MLYS stock forecast, quote, news & analysis
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone... Show more
Why Mineralys Therapeutics (MLYS) Stock Is Down -25.5% in the Last 30 Days
Key Takeaways
- Mineralys Therapeutics (MLYS) shares have fallen roughly 25.5% over the last 30 days, sliding from a closing price of $25.13 on September 30, 2026, to around $18.72.
- The decline extends a broader retreat, with the stock down approximately 28% over the trailing three months.
- Mineralys remains a pre-revenue, single-asset biotech, and its Q2 2026 net loss widened to $241.1 million, partly reflecting a one-time $200 million royalty repurchase.
- Positive lorundrostat data presented at two major medical meetings during the period did not reverse the selling pressure.
- A $150 million equity offering and competitive concerns around AstraZeneca's baxdrostat weighed on investor sentiment.
- The primary upcoming catalyst is the FDA's December 22, 2026 PDUFA target action date for lorundrostat.
- For more detailed data, explore the company's Price Targets, Earnings, and Forecast pages.
- Investors seeking automated strategies can explore Trending AI Robots for additional market insights.
Mineralys Therapeutics (MLYS) Company Overview and Market Position
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on treating hypertension and related cardiorenal conditions. Its lead candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed to reduce aldosterone production by inhibiting the CYP11B2 enzyme. The company is pursuing approval in uncontrolled and resistant hypertension, with additional development efforts in chronic kidney disease and obstructive sleep apnea. Lorundrostat's pivotal Launch-HTN trial demonstrated placebo-adjusted systolic blood pressure reductions of 9.1 mmHg at week six and 11.7 mmHg at week 12. Mineralys targets a large addressable population of roughly 20 million U.S. adults with uncontrolled or resistant hypertension, a group in which less than half of patients reach their blood pressure goals with existing therapies.
Mineralys Therapeutics (MLYS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MLYS has declined approximately 25.5%, from a September 30, 2026, close of $25.13 to around $18.72. The decline has been broadly consistent rather than concentrated in a single event, with the stock drifting lower through October despite intermittent data-driven bounces. Over the trailing quarter, the pullback is even steeper: from a level near $26.19 in late July 2026, shares have lost roughly 28% of their value. Notably, the stock had briefly traded near $31 in early September before giving back those gains, reflecting a period of elevated volatility around clinical and regulatory milestones.
What Drove MLYS Stock Price in the Last 30 Days
The 30-day slide occurred even as Mineralys delivered positive clinical updates. On October 9, 2026, the company presented a new Launch-HTN analysis at the American Heart Association Hypertension Scientific Sessions showing that 46% of lorundrostat-treated participants reached the guideline-recommended systolic blood pressure target of less than 130 mmHg at week 12. Later in October, additional Launch-HTN analyses presented at ASN Kidney Week showed consistent blood pressure reductions in patients with chronic kidney disease and a 52% placebo-adjusted reduction in albuminuria among albuminuric participants.
Despite these data, the shares moved lower. Several factors appear to have outweighed the positive readouts. As a pre-revenue company, Mineralys continues to post substantial operating losses, and its Q2 2026 results revealed a net loss of $241.1 million driven in part by a one-time $200 million royalty repurchase. The company also completed a $150 million equity offering, introducing dilution. Competitive dynamics added further pressure, as investors weighed the potential commercial entry of AstraZeneca's (AZN) baxdrostat, another aldosterone synthase inhibitor, ahead of lorundrostat's approval. Broader risk-off sentiment across the biotechnology sector also contributed to the downward trend.
What Drove MLYS Stock Performance Over the Last Quarter
The quarterly decline reflects a longer-running repricing of a single-asset, pre-revenue company ahead of a binary regulatory decision. Following a run-up into early September, the stock has steadily trended lower as investors weighed financing needs, competitive positioning, and execution risk. The second-quarter report, released in August 2026, highlighted sharply higher expenses tied to commercial launch preparation and the royalty repurchase, alongside a financing package that included the $150 million equity raise and a $500 million senior secured term loan. While management reiterated a cash runway into 2028 and emphasized payer and key-opinion-leader engagement, the market has remained cautious about dilution and the company's dependence on a single product through the FDA review cycle.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a broader platform that offers hundreds of automated strategies trading thousands of tickers. Only the top-performing and most relevant bots appear in this featured section, and each bot differs in strategy, timeframe, and performance metrics. This allows traders and investors to compare approaches and monitor automated signals across a range of market conditions. Exploring this section can provide an additional, data-driven perspective for those tracking momentum and sentiment across the market.
MLYS Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term catalyst is the FDA's decision on lorundrostat, with a PDUFA target action date of December 22, 2026. Investors will also monitor label and post-approval discussions, commercial launch preparations, and the company's ability to secure broad payer access. Competitive developments, including the commercial trajectory of AstraZeneca's baxdrostat, could shape the aldosterone synthase inhibitor market. Financial considerations remain relevant as well, including cash burn, the sufficiency of the runway into 2028, and any future financing activity. Further data presentations across chronic kidney disease and other indications could also influence the longer-term narrative. As with any clinical-stage biopharmaceutical company, regulatory outcomes and execution risk remain key variables.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MLYS in upward trend: price may jump up because it broke its lower Bollinger Band on October 30, 2026
MLYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 29 cases where MLYS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLYS advanced for three days, in 169 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MLYS as a result. In 43 of 60 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for MLYS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 36 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MLYS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.460) is normal, around the industry mean (3.498). P/E Ratio (-3.650) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. MLYS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLYS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology